STOCK TITAN

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Xilio Therapeutics, Inc. announced René Russo's participation in the 'Novel Immuno-Oncology' panel discussion at the TD Cowen 44th Annual Health Care Conference. The event will take place on March 4, 2024, at 10:30 am EST, with a live webcast available on the company's website.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion during the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 am EST.

A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary geographically precise solutions (GPS) platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:                
   
Investors:
Melissa Forst
Argot Partners
Xilio@argotpartners.com
 Media:
Dan Budwick
1AB
dan@1abmedia.com
   

FAQ

When is René Russo participating in the 'Novel Immuno-Oncology' panel discussion?

René Russo will participate in the 'Novel Immuno-Oncology' panel discussion on March 4, 2024, at 10:30 am EST.

Where can the live webcast of the event be accessed?

The live webcast can be accessed under 'Events & Presentations' in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/.

How long will the replay of the webcast be available on the website?

The replay of the webcast will be archived on the website for 30 days following the presentation.

Xilio Therapeutics, Inc.

NASDAQ:XLO

XLO Rankings

XLO Latest News

XLO Stock Data

38.78M
25.97M
40.92%
33.5%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM